Diferencia entre revisiones de «SGLT-2 Inhibitor»
(Add See Also section)
 
Línea 19: Línea 19:
==Mechanism of Action==
==Mechanism of Action==
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule
*Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule
==See Also==
*[[Diabetes medications]]
*[[Diabetic ketoacidosis]]
*[[Hyperglycemia]]


==References==
==References==

Revisión actual - 09:14 22 mar 2026

Administration

  • Type: Oral Diabetes medication
  • Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Euglycemic DKA[1]
  • Fournier's gangrene (rare)

Common

Mechanism of Action

  • Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule

See Also

References

  1. ↑ FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
Obtenido de «https://www.wikem.org/w/index.php?title=SGLT-2_Inhibitor&oldid=389019»